245 related articles for article (PubMed ID: 24330123)
1. Modulation of the TRPV1 channel: current clinical trials and recent patents with focus on neurological conditions.
De Petrocellis L; Moriello AS
Recent Pat CNS Drug Discov; 2013 Dec; 8(3):180-204. PubMed ID: 24330123
[TBL] [Abstract][Full Text] [Related]
2. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
Voight EA; Kort ME
Expert Opin Ther Pat; 2010 Sep; 20(9):1107-22. PubMed ID: 20586701
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
Wong GY; Gavva NR
Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
[TBL] [Abstract][Full Text] [Related]
4. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
Cui M; Honore P; Zhong C; Gauvin D; Mikusa J; Hernandez G; Chandran P; Gomtsyan A; Brown B; Bayburt EK; Marsh K; Bianchi B; McDonald H; Niforatos W; Neelands TR; Moreland RB; Decker MW; Lee CH; Sullivan JP; Faltynek CR
J Neurosci; 2006 Sep; 26(37):9385-93. PubMed ID: 16971522
[TBL] [Abstract][Full Text] [Related]
5. Disease-related changes in TRPV1 expression and its implications for drug development.
Premkumar LS; Bishnoi M
Curr Top Med Chem; 2011; 11(17):2192-209. PubMed ID: 21671875
[TBL] [Abstract][Full Text] [Related]
6. Polymodal Transient Receptor Potential Vanilloid Type 1 Nocisensor: Structure, Modulators, and Therapeutic Applications.
Cui M; Gosu V; Basith S; Hong S; Choi S
Adv Protein Chem Struct Biol; 2016; 104():81-125. PubMed ID: 27038373
[TBL] [Abstract][Full Text] [Related]
7. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.
Szallasi A; Cortright DN; Blum CA; Eid SR
Nat Rev Drug Discov; 2007 May; 6(5):357-72. PubMed ID: 17464295
[TBL] [Abstract][Full Text] [Related]
8. Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).
Lee Y; Hong S; Cui M; Sharma PK; Lee J; Choi S
Expert Opin Ther Pat; 2015 Mar; 25(3):291-318. PubMed ID: 25666693
[TBL] [Abstract][Full Text] [Related]
9. TRPV1 signaling: mechanistic understanding and therapeutic potential.
Xia R; Samad TA; Btesh J; Jiang LH; Kays I; Stjernborg L; Dekker N
Curr Top Med Chem; 2011; 11(17):2180-91. PubMed ID: 21671876
[TBL] [Abstract][Full Text] [Related]
10. A patent review of transient receptor potential vanilloid type 1 modulators (2014-present).
Gao M; Wang Y; Liu L; Qiao Z; Yan L
Expert Opin Ther Pat; 2021 Feb; 31(2):169-187. PubMed ID: 33377418
[No Abstract] [Full Text] [Related]
11. TRPV1-Targeted Drugs in Development for Human Pain Conditions.
Iftinca M; Defaye M; Altier C
Drugs; 2021 Jan; 81(1):7-27. PubMed ID: 33165872
[TBL] [Abstract][Full Text] [Related]
12. Activation of the transient receptor potential vanilloid-1 (TRPV1) channel opens the gate for pain relief.
Jancsó G; Dux M; Oszlács O; Sántha P
Br J Pharmacol; 2008 Dec; 155(8):1139-41. PubMed ID: 18997813
[TBL] [Abstract][Full Text] [Related]
13. Modulation of TRPV1 channel function by natural products in the treatment of pain.
Abbas MA
Chem Biol Interact; 2020 Oct; 330():109178. PubMed ID: 32738201
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
Gunthorpe MJ; Chizh BA
Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
[TBL] [Abstract][Full Text] [Related]
15. TRPV1 antagonists as a potential treatment for hyperalgesia.
Roberts LA; Connor M
Recent Pat CNS Drug Discov; 2006 Jan; 1(1):65-76. PubMed ID: 18221192
[TBL] [Abstract][Full Text] [Related]
16. Vanilloid receptor antagonists: emerging class of novel anti-inflammatory agents for pain management.
Pal M; Angaru S; Kodimuthali A; Dhingra N
Curr Pharm Des; 2009; 15(9):1008-26. PubMed ID: 19275664
[TBL] [Abstract][Full Text] [Related]
17. TRPV1: a therapeutic target for novel analgesic drugs?
Szallasi A; Cruz F; Geppetti P
Trends Mol Med; 2006 Nov; 12(11):545-54. PubMed ID: 16996800
[TBL] [Abstract][Full Text] [Related]
18. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
19. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics.
Maione S; Costa B; Piscitelli F; Morera E; De Chiaro M; Comelli F; Boccella S; Guida F; Verde R; Ortar G; Di Marzo V
Pharmacol Res; 2013 Oct; 76():98-105. PubMed ID: 23911581
[TBL] [Abstract][Full Text] [Related]
20. Targeting TRPV1 for pain relief: limits, losers and laurels.
Szallasi A; Sheta M
Expert Opin Investig Drugs; 2012 Sep; 21(9):1351-69. PubMed ID: 22780443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
